Effect of Multi-Modal Training in Patients With Mild Cognitive Impairment: A Randomized Controlled Pilot Trial.

Med Sci MonitSep 26, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Jing Chen, Zheli Chen, Fei Fang et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the effects of a 24-week multi-modal training program on cognitive function in 65 older adults with mild cognitive impairment (MCI). The intervention group showed significant improvements in cognitive scores compared to the control group, with a difference of 1.88 points in the Mini-Mental State Examination (MMSE) and 1.62 points in the Montreal Cognitive Assessment (MoCA), both with P<0.001.

Key findings

  • The intervention group improved by 1.88 points in MMSE compared to controls (P<0.001).
  • The intervention group improved by 1.62 points in MoCA compared to controls (P<0.001).
  • Significant group × time interactions were observed for both MMSE and MoCA (P<0.001).
  • Exploratory analyses indicated nominal declines in naming, memory, and attention in controls.

Why it matters

Improving cognitive function in older adults with mild cognitive impairment is crucial for enhancing quality of life and delaying progression to dementia. This study suggests that multi-modal training may be a beneficial intervention.

Source

PubMed · PMID 42798168

Published in Med Sci Monit. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.